Adimab
Latest round
- Series F
Last raised
- Mar 2012
Total raised
- $40M
Investors
- 5
About Adimab
Founded in 2007 in Lebanon, US, Adimab, LLC specializes in biologics discovery, particularly in antibody development. The company has not undergone any significant pivots or changes in its fundamental operations.Adimab specializes in biologics discovery and engineering, focusing on the development of antibodies and multispecific therapeutics. Utilizing a proprietary yeast-based platform, the company creates a diverse range of therapeutic candidates including IgGs, single domain antibodies (HCAbs), and multispecific leads.Adimab generates revenue primarily through strategic partnerships and collaborations with pharmaceutical and biotech companies. Revenue also comes from milestone payments related to projects as they progress.Adimab aims to innovate its product offerings by advancing its current platform for generating multispecific therapeutics, with no specific launch dates provided. The firm is looking to expand its reach within the US and into key European markets by leveraging its existing partnerships.8 mn will be utilized to support these growth initiatives, ensuring that the company effectively scales its operations and develops new therapeutic candidates.
Who invested in Adimab
5 investors across 6 rounds
See all investors in Adimab
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adimab
Who invested in Adimab?
Adimab has 5 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adimab raised?
Adimab has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Adimab last raise money?
Adimab's most recent round on record is a Series F, in Mar 2012.
What does Adimab do?
Founded in 2007 in Lebanon, US, Adimab, LLC specializes in biologics discovery, particularly in antibody development.
Where is Adimab headquartered?
Adimab is headquartered in Lebanon, US.
Which VCs invest in companies like Adimab?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Adimab's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series F
Raising like Adimab? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.